



Optimising outcomes in patients with venous thromboembolism (VTE)

Saturday 14th November 2020
9.30am - 11.30am

Webinar

At this event

- Listen to local and national experts in the field
- Enhance your knowledge in treating secondary prevention of VTE
- Understand the risk of VTE recurrence and secondary prevention of VTE in patients with cancer associated thrombosis (CAT)
- Learn about practical considerations for patients with VTE in light of the current global Covid-19 pandemic
- Receive a certificate for your appraisal portfolio

Meet the Speakers ...

Professor Ahmet Fuat PhD FRCGP FRCP (London) FRCP (Edinburgh) PGDiP Cardiology

Professor Ahmet Fuat has been a GP in Darlington, Co. Durham for 33 years. He has been a GPSI Cardiology for 20 years having undertaken a Postgraduate Diploma in Cardiology at Bradford University graduating with distinction. He started the first one stop diagnostic and integrated heart failure clinic in the UK 17 years ago with local colleagues.



His PhD by research in heart failure diagnosis and management including work on natriuretic peptides generated several publications that have informed guidelines and led to the award of an Honorary Professorial Chair at Durham University.

He holds various roles in CVD and research including the immediate past President of the Primary Care Cardiovascular Society (PCCS) which he was instrumental in reforming, CVD Clinical Adviser to the RCGP, CVD and Research Leads for Darlington Primary Care Network (PCN) and Federation, Associate Lead for Industry Research at North East and North Cumbria NIHR CRN. He has recently been elected onto the newly formed Darlington PCN Governing body as a GP member and Chair.

He has a passion for medical education and remains an active lecturer, tutor and researcher. He is on the editorial boards of the British Journal of Cardiology and Primary Care Cardiovascular Journals and a peer reviewer for most high impact Cardiovascular journals and research bodies. His work in community cardiology has been recognised with Fellowships from the RCGP, RCP London and RCP Edinburgh.

Professor Terry McCormack MBBS, DRCOG, MRCA, FBIHS, FESC

Terry McCormack is a GP in Whitby, North Yorkshire, Honorary Professor of Primary Care Cardiovascular Medicine at Hull York Medical School (HYMS) and Vice-President of the British and Irish Hypertension Society.

He is a primary care researcher, particularly interested in hypertension, lipids and anticoagulation.

In 2016 he received a National Institute of Health Research award for success in commercial research and in 2020 he was the winner of the HYMS Undergraduate Medicine Phase II and III Teacher of Excellence Award.

Guideline work includes the NICE Hypertension, Perioperative Care and Venous Thromboembolism guideline committees and the AAGBI/BHS preoperative BP guideline.

He is an editor of the British Journal of Cardiology and a Fellow of the European Society of Cardiology.



Your Learning Agenda ...

Optimising outcomes in patients with VTE

VTE is a collective term for both DVT and PE. With an estimated incidence rate of 1-2 per 1,000 of the population in the UK, VTE is a significant cause of mortality and disability in England with thousands of deaths directly attributed to it each year. One in twenty people will have VTE during their lifetime (reference: <http://apptg.org.uk/>).

VTE poses a significant burden on the NHS with an estimated annual cost of £ 146.7 million (reference: <http://apptg.org.uk/wp-content/uploads/APPTG-annual-survey-report-2018-compressed.pdf>).

At this patient case-based webinar, you will have the opportunity to look at practical implementation of relevant guidelines to optimise outcomes in patients with VTE.

This webinar covers practical guidance on the management and treatment of patients with acute VTE. It further covers the risk of VTE recurrence to understand which patient may benefit from extended anticoagulation, as well as the secondary prevention of VTE in patients with CAT.

In response to pressures on the NHS, the way health care professionals deliver anticoagulants may need to change. NHS England has recently published a clinical guide for the management of anticoagulant services during the coronavirus pandemic

<https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Coronavirus/FINAL%20Guidance%20on%20safe%20switching%20of%20warfarin%20to%20DOAC%20COVID-19%20Mar%202020.pdf?ver=2020-03-26-180945-627>

The clinical guide states transitioning appropriate patients from warfarin to a DOAC may be considered to avoid regular blood tests for INR monitoring. Whilst DOACs require blood tests to assess hepatic/renal function throughout treatment - the monitoring is predictable, less rigorous than INR testing with warfarin and is routinely carried out in primary care.

This programme will be led by Professor Ahmet Fuat and Professor Terry McCormack

Your Learning Agenda...

Part 1

- ▶ VTE: The medical and societal burden

Part 2

- ▶ Managing the patient with acute VTE

Part 3

- ▶ Treat and protect the patient with acute PE

Part 4

- ▶ Understanding the risk of VTE recurrence: Who needs extended anticoagulation?

Part 5

- ▶ Secondary prevention of VTE in patients with CAT

Part 6

- ▶ Patients with Non Valvular Atrial Fibrillation or VTE: Practical considerations for transitioning eligible patients from warfarin to a DOAC
 - Practical considerations and guidelines in the current global Covid-19 pandemic

Programme ...

COURSE CODE 1462

- 9.30am - 10.30am VTE: The medical and societal burden
Managing the patient with acute VTE
Treat and protect the patient with acute PE
Understanding the risk of VTE recurrence: Who needs extended anticoagulation?
- 10.30am - 10.40am Break
- 10.40am - 11.30am Secondary prevention of VTE in patients with CAT
Patients with NVAF or VTE: Practical considerations for transitioning eligible patients from warfarin to a DOAC
Questions and Answers

Book online at <https://www.mediconf.co.uk/Event-Details-Preview.aspx?id=1410>

WE DO NOT TAKE BOOKINGS OVER THE PHONE

Please note that all confirmations will be sent to you via email ONLY acknowledging your place, candidate registration number and other essential information.

MediConf do not release delegate emails to 3rd parties. Occasionally we may use email addresses to inform you of future events or services provided by our supporting organisations. Facilities are available for you to unsubscribe to this at any time.

The personal data provided by you to register for an event is used to process your booking request and for post event follow up information and feedback. For more information, please refer to our privacy policy which can be found at <https://www.mediconf.co.uk/Profile.aspx> where you may also find further information about processing of personal data and your rights. If you need any further information please contact the Data Processing Manager: Janet Poyner E. janet@mediconf.co.uk

If you register to attend an event, your personal data (name, professional title, work address) will be provided to the meeting sponsor, Bayer plc, who will use your personal data for the purposes of customer relationship management and record-keeping in accordance with compliance requirements. Bayer is an independent data controller of your personal data for these purposes. For more information on how Bayer holds your personal data, please see Bayer's privacy policy at www.bayer.co.uk/en/information-on-data-privacy-for-hcps

For a full list of our booking terms and conditions please visit our website: www.mediconf.co.uk

IF YOU DO NOT RECEIVE YOUR CONFIRMATION WITHIN 48 HOURS please contact the office

**MediConf UK Ltd | 19 Wood Street | Lytham St Annes | Lancashire | FY8 1QR
T. 01253 712894 | W. www.mediconf.co.uk | E. rebecca@mediconf.co.uk**

Bayer medicinal product(s) will be discussed and relevant prescribing information(s) will be available during the webinar

RP-XAR-GB-2609 | Date of Preparation: October 2020 • In conjunction with MediConf, this online event has been organised and fully funded by Bayer